Elevated THBS3 predicts poor overall survival for clear cell renal cell carcinoma and identifies LncRNA/RBP/THBS3 mRNA networks

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245–261.
   PubMed Web of Science ®Google Scholar
• Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556–1563.
   PubMed Web of Science ®Google Scholar
• Sid B, Sartelet H, Bellon G, et al. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol. 2004;49(3):245–258.
   PubMed Web of Science ®Google Scholar
• Chu XD, Lin ZB, Huang T, et al. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer. BMC Cancer. 2022;22(1):250. DOI:10.1186/s12885-022-09201-3
   PubMed Web of Science ®Google Scholar
• Qu HL, Hasen GW, Hou YY, et al. THBS2 promotes cell migration and invasion in colorectal cancer via modulating Wnt/β-catenin signaling pathway. Kaohsiung J Med Sci. 2022;38(5):469–478.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen J, Gao WQ, et al. METTL14 promotes prostate tumorigenesis by inhibiting THBS1 via an m6a-YTHDF2-dependent mechanism. Cell Death Discov. 2022;8(1):143.
   PubMed Web of Science ®Google Scholar
• Adolph KW, Long GL, Winfield S, et al. Structure and organization of the human thrombospondin 3 gene (THBS3). Genomics. 1995;27(2):329–336.
   PubMed Web of Science ®Google Scholar
• Vos HL, Devarayalu S, de Vries Y, et al. Thrombospondin 3 (Thbs3), a new member of the thrombospondin gene family. J Biol Chem. 1992;267(17):12192–12196.
   PubMed Web of Science ®Google Scholar
• Dalla-Torre CA, Yoshimoto M, Lee CH, et al. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer. 2006;6(1):237.
   PubMedGoogle Scholar
• Kanehisa M, Furumichi M, Tanabe M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–d361.
   PubMed Web of Science ®Google Scholar
• Wang G, Qu F, Liu S, et al. Nucleolar protein NOP2 could serve as a potential prognostic predictor for clear cell renal cell carcinoma. Bioengineered. 2021;12(1):4841–4855.
   PubMed Web of Science ®Google Scholar
• Hundal J, Carreno BM, Petti AA, et al. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8(1):11.
   PubMed Web of Science ®Google Scholar
• Boegel S, Löwer M, Schäfer M, et al. HLA typing from RNA-seq sequence reads. Genome Med. 2012;4(12):102.
   PubMedGoogle Scholar
• Shen-Orr SS, Gaujoux R. Computational deconvolution: extracting cell type-specific information from heterogeneous samples. Curr Opin Immunol. 2013;25(5):571–578.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
   PubMed Web of Science ®Google Scholar
• Mu M, Yu Q, Zhang Q, et al. A pan-cancer analysis of molecular characteristics and oncogenic role of gasdermins. Cancer Cell Int. 2022;22(1):80.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tian Y, Liu S, et al. Prognostic value and immunological role of AXL gene in clear cell renal cell carcinoma associated with identifying LncRNA/RBP/AXL mRNA networks. Cancer Cell Int. 2021;21(1):625.
   PubMed Web of Science ®Google Scholar
• Adams J, Lawler J. Extracellular matrix: the thrombospondin family. Curr Biol. 1993;3(3):188–190.
   PubMed Web of Science ®Google Scholar
• Lawler J. Thrombospondins. Curr Drug Targets. 2008;9(10):820–821.
   PubMed Web of Science ®Google Scholar
• Frazier WA. Thrombospondins. Curr Opin Cell Biol. 1991;3(5):792–799.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Li H, et al. THBS2 is a potential prognostic biomarker in colorectal cancer. Sci Rep. 2016;6:33366.
   PubMed Web of Science ®Google Scholar
• Hankenson KD, Hormuzdi SG, Meganck JA, et al. Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol. 2005;25(13):5599–5606.
   PubMed Web of Science ®Google Scholar
• Fehringer G, Kraft P, Pharoah PD, et al. Cross-Cancer genome-wide analysis of lung, ovary, breast, prostate, and colorectal cancer reveals novel pleiotropic associations. Cancer Res. 2016;76(17):5103–5114. DOI:10.1158/0008-5472.CAN-15-2980
   PubMed Web of Science ®Google Scholar
• Deng LY, Zeng XF, Tang D, et al. Expression and prognostic significance of thrombospondin gene family in gastric cancer. J Gastrointest Oncol. 2021;12(2):355–364.
   PubMed Web of Science ®Google Scholar
• Teraoku H, Morine Y, Ikemoto T, et al. Role of thrombospondin-1 expression in colorectal liver metastasis and its molecular mechanism. J Hepatobiliary Pancreat Sci. 2016;23(9):565–573.
   PubMed Web of Science ®Google Scholar
• Chen PC, Tang CH, Lin LW, et al. Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression. J Hematol Oncol. 2017;10(1):33.
   PubMedGoogle Scholar
• Su F, Zhao J, Qin S, et al. Over-Expression of thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinoma. Oncotarget. 2017;8(14):23277–23288. DOI:10.18632/oncotarget.15054
   PubMedGoogle Scholar
• Harrison GS, Wierman ME, Nett TM, et al. Gonadotropin-Releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer. 2004;11(4):725–748.
   PubMed Web of Science ®Google Scholar
• Gründker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. Front Endocrinol (Lausanne). 2017;8:187.
   PubMed Web of Science ®Google Scholar
• Jayaram S, Gupta MK, Raju R, et al. Multi-Omics data integration and mapping of altered kinases to pathways reveal gonadotropin hormone signaling in glioblastoma. Omics. 2016;20(12):736–746.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun T, Sun H, et al. SCF/C-Kit/jnk/ap-1 signaling pathway promotes claudin-3 expression in colonic epithelium and colorectal carcinoma. Int J Mol Sci. 2017;18(4):765.
   PubMed Web of Science ®Google Scholar
• Quang CT, Leboucher S, Passaro D, et al. The calcineurin/nfat pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells. Cell Death Amp Dis. 2015;6(2):e1658.
   PubMedGoogle Scholar
• Najafi M, Ahmadi A, Mortezaee K. Extracellular-Signal-Regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review. Cell Biol Int. 2019;43(11):1206–1222.
   PubMed Web of Science ®Google Scholar
• Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs. 2013;73(7):613–623.
   PubMed Web of Science ®Google Scholar
• Dormoy V, Danilin S, Lindner V, et al. The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. Mol Cancer. 2009;8(1):123.
   PubMedGoogle Scholar
• D’Amato C, Rosa R, Marciano R, et al. Inhibition of hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014;111(6):1168–1179. DOI:10.1038/bjc.2014.421
   PubMed Web of Science ®Google Scholar
• Zhou J, Wu K, Gao D, et al. Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014;90(4):942–951. DOI:10.1016/j.ijrobp.2014.06.065
   PubMed Web of Science ®Google Scholar
• Kamada S, Takeiwa T, Ikeda K, et al. Emerging roles of COX7RP and mitochondrial oxidative phosphorylation in breast cancer. Front Cell Dev Biol. 2022;10:717881.
   PubMed Web of Science ®Google Scholar
• Xu T, Junge JA, Delfarah A, et al. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Sci Rep. 2022;12(1):5518. DOI:10.1038/s41598-022-09438-9
   PubMed Web of Science ®Google Scholar
• Xue D, Xu Y, Kyani A, et al. Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancer. J Med Chem. 2022;65(4):3404–3419.
   PubMed Web of Science ®Google Scholar
• Palmeri M, Mehnert J, Silk AW, et al. Real-World application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1):100336. DOI:10.1016/j.esmoop.2021.100336
   PubMed Web of Science ®Google Scholar
• Park R, Da Silva LL, Saeed A. Immunotherapy predictive molecular markers in advanced gastroesophageal cancer: mSI and beyond. Cancers (Basel). 2021;13(7).
   Web of Science ®Google Scholar
• Zheng Y, Fu Y, Wang PP, et al. Neoantigen: a promising target for the immunotherapy of colorectal cancer. Dis Markers. 2022;2022:8270305.
   PubMed Web of Science ®Google Scholar
• Lan Y, Xiao X, He Z, et al. Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer. Nucleic Acids Res. 2018;46(11):5809–5821.
   PubMed Web of Science ®Google Scholar
• Janakiraman H, House RP, Gangaraju VK, et al. The long (lncRNA) and short (miRNA) of it: tGFβ-mediated control of RNA-binding proteins and noncoding RNAs. Mol Cancer Res. 2018;16(4):567–579.
   PubMed Web of Science ®Google Scholar
• Ni T, Guo D, Tan L, et al. NPSR1-AS1 activates the MAPK pathway to facilitate thyroid cancer cell malignant behaviors via recruiting ELAVL1 to stabilize NPSR1 mRNA. Cell Cycle (Georgetown, Tex). 2022;21(5):439–449.
   PubMed Web of Science ®Google Scholar
• Zhu L, Liu Y, Tang H, et al. FOXP3 activated-LINC01232 accelerates the stemness of non-small cell lung carcinoma by activating TGF-β signaling pathway and recruiting IGF2BP2 to stabilize TGFBR1. Exp Cell Res. 2022;413(2):113024.
   PubMed Web of Science ®Google Scholar